AgomAb Therapeutics NV
NASDAQAGMB enters the week after earnings with an unusually clean analyst build and a short book that has been unwinding steadily — the tension is whether the Street's conviction translates into price recovery after a 7.5% weekly pullback. The most striking development is the analyst coverage build. Cantor Fitzgerald initiated with an Overweight rating on August 19 — the most recent…
Snapshot as of 20 Aug 2026
AGMB enters the week after earnings with an unusually clean analyst build and a short book that has been unwinding steadily — the tension is whether the Street's conviction translates into price recovery after a 7.5%…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for AGMB — free to start on ORTEX.
Sign up for free →Open AGMB on ORTEX